Serzone (nefazodone HCl)
February 13, 2003
Audience: Neuropsychiatric healthcare professionals and Pharmacists
Bristol-Myers Squibb notified healthcare professionals of medication errors due to name confusion between Serzone, indicated for the treatment of depression, and Seroquel, a product of AstraZeneca, indicated for the treatment of schizophrenia. The overlapping strengths (100 mg and 200 mg), the dosage form (tablets), the dosing interval (BID), and the fact that these two products are stocked close together in pharmacies were critical in causing these medication errors.[December 9, 2002 Letter - Bristol-Myers Squibb] PDF Format
Past MedWatch alerts:
[May 20, 2002 Letter - AstraZeneca] (Seroquel alert)
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.